{"id":"subcutaneous-depot-medroxyprogesterone-acetate","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Irregular bleeding or amenorrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"2-5","effect":"Weight gain"},{"rate":"2-5","effect":"Mood changes"},{"rate":"1-5","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL287148","moleculeType":"Small molecule","molecularWeight":"386.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a long-acting reversible contraceptive, subcutaneous depot medroxyprogesterone acetate works by inhibiting the luteinizing hormone (LH) surge needed for ovulation. It also thickens cervical mucus to impede sperm transport and alters the endometrium to prevent implantation. The subcutaneous depot formulation provides sustained hormone release over approximately 13 weeks.","oneSentence":"Medroxyprogesterone acetate is a synthetic progestin that prevents pregnancy by suppressing ovulation and altering the uterine environment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:50.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT05505435","phase":"PHASE4","title":"Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2022-08-01","conditions":"Contraception","enrollment":263},{"nctId":"NCT04997499","phase":"NA","title":"Adolescent Subcutaneous (SQ) Injection Video Validation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2021-09-29","conditions":"Medication Compliance, Contraception, Self-Evaluation","enrollment":30},{"nctId":"NCT04814927","phase":"PHASE4","title":"Impact of Contraceptives on Cervico-Vaginal Mucosa","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2021-03-01","conditions":"Mucosal Inflammation, Contraceptive; Complications, Intrauterine","enrollment":112},{"nctId":"NCT03255941","phase":"EARLY_PHASE1","title":"Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers","status":"COMPLETED","sponsor":"FHI 360","startDate":"2018-03-19","conditions":"Contraception","enrollment":460},{"nctId":"NCT02509767","phase":"PHASE4","title":"Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood","status":"COMPLETED","sponsor":"Planned Parenthood Federation of America","startDate":"2015-08","conditions":"Contraception","enrollment":401},{"nctId":"NCT01019369","phase":"NA","title":"Study of Self or Clinic Administration of DepoProvera","status":"COMPLETED","sponsor":"Carolyn L. Westhoff","startDate":"2010-03","conditions":"Contraception","enrollment":132},{"nctId":"NCT02456584","phase":"PHASE1","title":"Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods","status":"COMPLETED","sponsor":"FHI 360","startDate":"2015-09","conditions":"Contraception","enrollment":42},{"nctId":"NCT00437658","phase":"PHASE2","title":"Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2006-12-11","conditions":"Endometriosis","enrollment":252},{"nctId":"NCT02732418","phase":"PHASE1","title":"Lower Dose Depo Provera® Contraceptive Injection","status":"COMPLETED","sponsor":"FHI 360","startDate":"2016-12-02","conditions":"Contraception","enrollment":60},{"nctId":"NCT01299116","phase":"PHASE4","title":"Long-Acting Reversible Contraception","status":"COMPLETED","sponsor":"FHI 360","startDate":"2011-12","conditions":"Contraception","enrollment":916},{"nctId":"NCT02293694","phase":"NA","title":"Sayana® Press Self-injection Study in Malawi","status":"COMPLETED","sponsor":"FHI 360","startDate":"2015-09-17","conditions":"Contraception","enrollment":735},{"nctId":"NCT01143207","phase":"NA","title":"PK of Depo SubQ Injected in the Upper Arm","status":"COMPLETED","sponsor":"FHI 360","startDate":"2010-05","conditions":"Contraception","enrollment":26},{"nctId":"NCT00770887","phase":"","title":"Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Fertility","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["depo-subQ provera 104™"],"phase":"marketed","status":"active","brandName":"Subcutaneous depot medroxyprogesterone acetate","genericName":"Subcutaneous depot medroxyprogesterone acetate","companyName":"Planned Parenthood Federation of America","companyId":"planned-parenthood-federation-of-america","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Medroxyprogesterone acetate is a synthetic progestin that prevents pregnancy by suppressing ovulation and altering the uterine environment. Used for Contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}